ArticleJournal of biomedical optics2016
Focused ultrasound-mediated sonochemical internalization: an alternative to light-based therapies.
Article in Journal of biomedical optics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.Journal of neuro-oncology · 2024Pooled it
- Inhibiting glioma cell invasion by sequential photo-sonodynamic therapy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- In Vitro Sonodynamic Therapy Using a High Throughput 3D Glioblastoma Spheroid Model with 5-ALA and TMZ Sonosensitizers.Advanced healthcare materials · 2024Article
- Ultrasound Responsive Nanovaccine Armed with Engineered Cancer Cell Membrane and RNA to Prevent Foreseeable Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.Journal of neuro-oncology · 2023Review
- Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review.Pharmaceutics · 2023Review
- Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives.Military Medical Research · 2022Review
- Diaryliodonium salts facilitate metal-free mechanoredox free radical polymerizations.Chemical science · 2022Article
- Sonodynamic therapy for gliomas.Journal of neuro-oncology · 2022Review
- Manipulation of Mitophagy by "All-in-One" nanosensitizer augments sonodynamic glioma therapy.Autophagy · 2020Article
- Ultrasound-Activated Cascade Effect for Synergistic Orthotopic Pancreatic Cancer Therapy.iScience · 2020Article
- Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research.Journal of clinical medicine · 2020Review
- Synergistic efficacy of ultrasound, sonosensitizers and chemotherapy: a review.Therapeutic delivery · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Activation of sonosensitizers via focused ultrasound (FUS), i.e., sonodynamic therapy has been proposed as an extension to light-activated photodynamic therapy for the treatment of brain as well as other tumors. The use of FUS, as opposed to light, allows treatment to tumor sites buried deep within tissues as well as through the intact skull. We have examined ultrasonic activation of sonosensitizers together with the anticancer agent bleomycin (BLM), i.e., sonochemical internalization (SCI). SCI is a technique that utilizes FUS for the enhanced delivery of endo-lysosomal trapped macromolecules into the cell cytoplasm in a similar manner to light-based photochemical internalization. The released agent can, therefore, exert its full biological activity, in contrast to being degraded by lysosomal hydrolases. Our results indicate that, compared to drug or FUS treatment alone, FUS activation of the sonosensitizer AlPcS2a together with BLM significantly inhibits the ability of treated glioma cells to grow as three-dimensional tumor spheroids in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.